GlassScriptPhysician profile
Jasmine Cofield
NPI 1487248795
$2,541.32
in general payments reported to CMS, 2019-2025
24 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $296 · 2022: $673 · 2023: $364 · 2024: $660 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404 · Consulting Fee: $115 · Education: $53.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.78 |
| Consulting Fee | $115.00 |
| Education | $53.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $643.96 | 2021-2025 | Rexulti, Abilify Mycite |
| Abbvie INC. | $341.31 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.36 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $204.24 | 2022-2024 | Spravato |
| Neurocrine Biosciences, INC. | $173.95 | 2023-2024 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $160.83 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $129.30 | 2022 | |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $86.18 | 2024-2025 | Qelbree |
| Lilly USA, LLC | $72.76 | 2021-2022 | |
| Novo Nordisk INC | $70.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.17 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.18 | 2021-2022 | |
| Amgen INC. | $38.93 | 2021-2022 | |
| Corium, LLC | $27.64 | 2024 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $19.51 | 2022 | |
| Alkermes, INC. | $18.50 | 2024 | Aristada, Lybalvi |
| Biohaven Pharmaceuticals, INC. | $18.32 | 2021 | |
| Glaxosmithkline, LLC. | $16.67 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.39 | 2021 | |
| Currax Pharmaceuticals LLC | $14.62 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.24 | 2021 | |
| Seqirus USA INC | $14.06 | 2022 | |
| Grt US Holding, INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Cofield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.